"We develop, make and market life saving products. In this way, we seek to exploit the tremendous rewards and growth potential available in this industry to deliver better treatments to patients and better returns to shareholders." Our plan is to use revenues from our marketed products and licensing income to help fund the development of a robust and high value pipeline of products. Protherics seeks to use industry collaborations and Mand;A to achieve our goals in an industry where critical mass is needed to achieve long-term growth. Our licensing deal with AstraZeneca for CytoFab, our severe sepsis product being prepared for Phase 3 development, is a key alliance for Protherics, and a truly transforming deal for the Company. Protherics could receive a total of $340m in upfront and milestone payments through to the successful development and launch of CytoFab in the challenging, but rewarding sepsis indication. Protherics will also receive a 20% royalty on net global sales of what could be a potential blockbuster product. We believe that Protherics is well positioned to emerge as a world-leading biopharmaceutical company, with the goal of delivering for its shareholders, employees, partners and patients.
This article uses content from
http://www.AboutUs.org
